• Our vision is to balance mother nature and human engineering to discover and develop innovative antibody therapeutics

Leadership Team
Peter (Peizhi) Luo
Founder and CEO

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.
Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.
Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Felix (Fangyong) Du
VP of Technology Development

Dr. Felix (Fangyong) Du is the Vice President of Technology Development at Adagene. He has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles, including original articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.
Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After acquisition of Affomix by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.
Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. degrees from Peking University.

Yan Li
VP of Bioinformatics and IT

Ms. Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.
Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from Nov 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to Dec 2010. She received the Merck Award for Excellence in "Innovative Technologies” with the team, and a Special Award for her contribution.
Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom. Ms. Li received her BSE in Information Science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.

Kristine (Xiaohong) She
VP of Operations

Ms. Kristine (Xiaohong) She serves as the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renown laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.
Ms. She received her M.S. degree from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S. degree from Wuhan University.

Alexander Goergen
Senior Director of Business Development

Alexander Goergen is the Senior Director of business development and head of licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationships in the pharmaceutical and biotech industry for the purpose of advancing human healthcare. Prior to joining Adagene, Alexander spent several years in business development for Catalent Pharma Solutions Biologics Division.
Alexander completed many licensing, manufacturing, and cell line development programs both domestically and internationally. Alexander was also in charge of managing a relationship with one of Catalent’s key global strategic accounts prior to joining Adagene. Before joining Catalent, Alexander has worked in various roles at the International AIDS Vaccine Initiative, Covance , and TRC. Alexander holds an M.S. from the School of Medicine and Public Health at the University of Wisconsin-Madison. He completed his undergraduate work at Lafayette College.

Leadership Team
  1. Peter Luo
    Founder and CEO
  2. Felix Du
    VP of Technology Development
  3. Yan Li
    VP of Bioinformatics and IT
  4. Kristine She
    VP of Operations
  5. Alexander Goergen
    Senior Director of Business Development
  • Peter (Peizhi) Luo

    Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.
    Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.
    Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

  • Felix (Fangyong) Du

    Dr. Felix (Fangyong) Du is the Vice President of Technology Development at Adagene. He has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles, including original articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.
    Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After acquisition of Affomix by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.
    Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. degrees from Peking University.

  • Yan Li

    Ms. Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.
    Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from Nov 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to Dec 2010. She received the Merck Award for Excellence in "Innovative Technologies” with the team, and a Special Award for her contribution.
    Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom.
    Ms. Li received her BSE in Information Science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.

  • Kristine (Xiaohong) She

    Ms. Kristine (Xiaohong) She serves as the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renown laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.
    Ms. She received her M.S. degree from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S. degree from Wuhan University.

  • Alexander Goergen

    Alexander Goergen is the Senior Director of business development and head of licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationships in the pharmaceutical and biotech industry for the purpose of advancing human healthcare. Prior to joining Adagene, Alexander spent several years in business development for Catalent Pharma Solutions Biologics Division.
    Alexander completed many licensing, manufacturing, and cell line development programs both domestically and internationally. Alexander was also in charge of managing a relationship with one of Catalent’s key global strategic accounts prior to joining Adagene. Before joining Catalent, Alexander has worked in various roles at the International AIDS Vaccine Initiative, Covance , and TRC. Alexander holds an M.S. from the School of Medicine and Public Health at the University of Wisconsin-Madison. He completed his undergraduate work at Lafayette College.

Board Of Directors
Peter(Peizhi) Luo, Ph.D.
Founder and CEO, Adagene

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.
Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.
Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Daniel Auerbach, M.B.A.
Biography Managing Partner, Asia, Eight Roads

Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the World’s largest, independent, privately held money management firms. Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the Development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.
Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.
Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.
In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.
Mr. Auerbach holds a B.A from Dartmouth College (1980) in Economics and Foreign Languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

Thomas R. Beck, M.D.
Executive Partner, F-Prime Capital

Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.
Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.
Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., and Symbiomix Therapeutics, and is an observer at Aclaris Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics. He currently is Head, Research and Development at Symbiomix.

Leon Chen, Ph.D.
Founding Partner and CEO, 6 Dimensions Capital

Leon Chen is the Founder and Managing Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital - one of the largest healthcare focused investment group with unique capability and extensive coverage across China and the US. Dr. Leon Chen became 6 Dimensions Capital’s CEO. Before founding Frontline BioVentures in 2012, Leon was a Partner with Fidelity Growth Partners Asia, and a Managing Partner with BioVeda China. Since 2005, Leon has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, TenNor Therapeutics, MDDF, Coherent Biopharma, Yikon Genomics, Huazhou, Bio Kangtai and Neusoft Medical.
Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies; past affiliations include McKinsey & Company, Ernst & Young LLP Leon also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
He received a BS degree from Peking University, a Ph.D. degree with top honor from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.

Li Li
Vice President, Sequoia China

Mr. Li Li has approximately 10 years of experiences in Healthcare industry and related Venture Capital & Private Equity investment, and is currently a vice president of Sequoia Capital China.
Mr. Li Li received his Bachelor Degree in Natural Sciences from University of Cambridge in UK. He was a Clinical Research Associate at Otsuka Beijing Research Institute a fully owned subsidiary of Otsuka Pharmaceutical (TYO:4578), an analyst and then an associate of the China Everbright Limited (00165.HK) Medical & Healthcare Fund, an associate of Sequoia Capital China. During the time at the China Everbright Limited Medical & Healthcare Fund, he participated the investments in BGI (300676), Amcare, Betta Pharma (300558) and Jida Pharma.

Amy Wang, Ph.D. M.D.
Partner IC Member, GP Healthcare Capital

Dr. Xiaoyan Wang received her PhD in Biology from Chinese Academy of Sciences, and MBA from Shanghai Advanced Institution of Finance (SAIF) of Shanghai Jiao Tong University. She was a product specialist of genome analysis at Beckman Coulter, the Vice General Manager of Bioscience, the director of core facility in Shanghai Institute of Biochemistry and Cell Biology, the investment manager of China-Singapore Suzhou Industrial Park Venture Capital Co., Ltd., and the investment director of Oriza Seed Fund Management Co., Ltd.
During Dr. Wang’s tenure at China-Singapore Suzhou Industrial Park Venture Capital and Oriza Seed Fund Management Co., Ltd, she led the investments in early or developing stage companies in medical devices, pharmaceuticals and medical services. She was in charge of 9 investments, including Innovent Biologics, CF PharmaTech, Bowing Medical, Ryan Nano, Sealand Technology, Tennor Therapeutics, etc. most of these companies have completed the follow-up financing.
Dr. Wang has more than 10 years experience in medical industry, and years of experience in health industry equity investment. Now she is MD and partner of GP Healthcare Capital Co., Ltd.

Board Of Directors
  1. Peter Luo
  2. Daniel Auerbach
  3. Thomas R. Beck
  4. Leon Chen
  5. Li Li
  6. Amy Wang
  • Peter(Peizhi) Luo, Ph.D.
    Founder and CEO, Adagene

    Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.
    Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.
    Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

  • Daniel Auerbach, M.B.A.
    Biography Managing Partner, Asia, Eight Roads

    Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the World’s largest, independent, privately held money management firms.
    Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the Development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.
    Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.
    Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.
    In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.
    Mr. Auerbach holds a B.A from Dartmouth College (1980) in Economics and Foreign Languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

  • Thomas R. Beck, M.D.
    Executive Partner, F-Prime Capital

    Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.
    Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.
    Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., and Symbiomix Therapeutics, and is an observer at Aclaris Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics. He currently is Head, Research and Development at Symbiomix.

  • Leon Chen, Ph.D.
    Founding Partner and CEO, 6 Dimensions Capital

    Leon Chen is the Founder and Managing Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital - one of the largest healthcare focused investment group with unique capability and extensive coverage across China and the US. Dr. Leon Chen became 6 Dimensions Capital’s CEO. Before founding Frontline BioVentures in 2012, Leon was a Partner with Fidelity Growth Partners Asia, and a Managing Partner with BioVeda China. Since 2005, Leon has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, TenNor Therapeutics, MDDF, Coherent Biopharma, Yikon Genomics, Huazhou, Bio Kangtai and Neusoft Medical.
    Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies; past affiliations include McKinsey & Company, Ernst & Young LLP Leon also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
    He received a BS degree from Peking University, a Ph.D. degree with top honor from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.

  • Li Li
    Vice President, Sequoia China

    Mr. Li Li has approximately 10 years of experiences in Healthcare industry and related Venture Capital & Private Equity investment, and is currently a vice president of Sequoia Capital China.
    Mr. Li Li received his Bachelor Degree in Natural Sciences from University of Cambridge in UK. He was a Clinical Research Associate at Otsuka Beijing Research Institute a fully owned subsidiary of Otsuka Pharmaceutical (TYO:4578), an analyst and then an associate of the China Everbright Limited (00165.HK) Medical & Healthcare Fund, an associate of Sequoia Capital China. During the time at the China Everbright Limited Medical & Healthcare Fund, he participated the investments in BGI (300676), Amcare, Betta Pharma (300558) and Jida Pharma.

  • Amy Wang, Ph.D. M.D.
    Partner IC Member, GP Healthcare Capital

    Dr. Xiaoyan Wang received her PhD in Biology from Chinese Academy of Sciences, and MBA from Shanghai Advanced Institution of Finance (SAIF) of Shanghai Jiao Tong University. She was a product specialist of genome analysis at Beckman Coulter, the Vice General Manager of Bioscience, the director of core facility in Shanghai Institute of Biochemistry and Cell Biology, the investment manager of China-Singapore Suzhou Industrial Park Venture Capital Co., Ltd., and the investment director of Oriza Seed Fund Management Co., Ltd.
    During Dr. Wang’s tenure at China-Singapore Suzhou Industrial Park Venture Capital and Oriza Seed Fund Management Co., Ltd, she led the investments in early or developing stage companies in medical devices, pharmaceuticals and medical services. She was in charge of 9 investments, including Innovent Biologics, CF PharmaTech, Bowing Medical, Ryan Nano, Sealand Technology, Tennor Therapeutics, etc. most of these companies have completed the follow-up financing.
    Dr. Wang has more than 10 years experience in medical industry, and years of experience in health industry equity investment. Now she is MD and partner of GP Healthcare Capital Co., Ltd.

INVESTORS
F-Prime Capital Partners
Learn more >

Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

fprimecapital.com
Eight Roads Ventures
Learn more >

Eight Roads Ventures (formerly Fidelity Growth Partners) is the venture arm of Eight Roads, the proprietary investment arm of Fidelity International Limited. As a private venture capital investor, Eight Roads Ventures is dedicated to long-term investment approach on ventures specialized in Healthcare and Biosciences, and Technology. A strong track record includes investments in Alibaba, WuXi PharmaTech, Innovent, Hua Medicine, Hile, etc.

www.eightroads.com
6 Dimensions Capital
Learn more >

6 Dimensions Capital was established in May, 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. The two prominent and experienced teams came together and formed a healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States.

www.6dimensionscapital.com
GP Healthcare Capital
Learn more >

GP Healthcare Capital, a subsidiary fund of GP Capital, is a professionally managed private equity fund which invests in disruptive technology and products within the healthcare industry. Our mission is to provide capital to innovative organizations with visionary leadership teams who are challenging the status quo of medicine as it is practiced globally. We work closely with entrepreneurs to achieve our vision of a "Value Discoverer" and "Value Creator".

www.gpcapital.com.cn
New World TMT Ltd
Learn more >

New World TMT Ltd (NWTMT) is the telecom, media and technology business management arm of the New World Group, one of Hong Kong's blue chip conglomerates. Comprising three operational areas - Telecom, Media and Technology - NWTMT invests and operates in innovative telemedia enterprises in China and the Asia Pacific region.
New World TMT is positioned to benefit from regional liberalization initiatives and technological advancement. By way of providing management support, strategic partnerships and capital, the company aims to maximize returns and create shareholder value for a portfolio of enterprises in which NWTMT has significant equity interest.

www.nwtmt.com
Sequoia China
Learn more >

The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 13 years we’ve had the privilege of working with more than 500 companies in China.

www.sequoiacap.com/china/en
INVESTORS
  • F-Prime Capital Partners

    Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

    Eight Roads Ventures

    Eight Roads Ventures (formerly Fidelity Growth Partners) is the venture arm of Eight Roads, the proprietary investment arm of Fidelity International Limited. As a private venture capital investor, Eight Roads Ventures is dedicated to long-term investment approach on ventures specialized in Healthcare and Biosciences, and Technology. A strong track record includes investments in Alibaba, WuXi PharmaTech, Innovent, Hua Medicine, Hile, etc.

    6 Dimensions Capital

    6 Dimensions Capital was established in May, 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. The two prominent and experienced teams came together and formed a healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States.

  • GP Healthcare Capital

    GP Healthcare Capital, a subsidiary fund of GP Capital, is a professionally managed private equity fund which invests in disruptive technology and products within the healthcare industry. Our mission is to provide capital to innovative organizations with visionary leadership teams who are challenging the status quo of medicine as it is practiced globally. We work closely with entrepreneurs to achieve our vision of a "Value Discoverer" and "Value Creator".

    New World TMT Ltd

    New World TMT Ltd (NWTMT) is the telecom, media and technology business management arm of the New World Group, one of Hong Kong's blue chip conglomerates. Comprising three operational areas - Telecom, Media and Technology - NWTMT invests and operates in innovative telemedia enterprises in China and the Asia Pacific region.
    New World TMT is positioned to benefit from regional liberalization initiatives and technological advancement. By way of providing management support, strategic partnerships and capital, the company aims to maximize returns and create shareholder value for a portfolio of enterprises in which NWTMT has significant equity interest.

    Sequoia China

    The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 13 years we’ve had the privilege of working with more than 500 companies in China.

KEY EVENTS
2018
03.26

Adagene announced a $50 million Series C financing led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.

2016
01.28

Adagene announced a $28 million Series B financing led by GP Healthcare Capital. Joining this round were new investor New World TMT and current investors Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), F-Prime Capital (formerly Fidelity Biosciences) and WuXi Corporate Venture Fund.

2014
12.08

Adagene announced the closing of an $8 million Series A financing with backing from Fidelity Biosciences, a leading investor in innovative world-class healthcare technologies; Fidelity Asia Growth, a leading investor in global innovative companies in Asia; and WuXi Venture Fund, the investment arm of WuXi PharmaTech, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States.

2012
02.28

Adagene established in Suzhou, China.

KEY EVENTS
2018.03.26

Adagene announced a $50 million Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.

2016.01.28

Adagene announced a $28 million Series B financing led by GP Healthcare Capital. Joining this round were new investor New World TMT and current investors Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), F-Prime Capital (formerly Fidelity Biosciences) and WuXi Corporate Venture Fund.

2014.12.08

Adagene announced the closing of an $8 million Series A financing with backing from Fidelity Biosciences, a leading investor in innovative world-class healthcare technologies; Fidelity Asia Growth, a leading investor in global innovative companies in Asia; and WuXi Venture Fund, the investment arm of WuXi PharmaTech, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States.

2012.02.28

Adagene established in Suzhou, China.

©Copyright-Adagene 2018